Humana Divests Gentiva Stake for $900 Million

Humana Inc. has officially entered into a definitive agreement to sell its minority interest in Gentiva, a prominent provider of hospice and palliative care services. The transaction, which is valued at approximately $900 million, involves a consortium of investors. While specific financial details remain undisclosed, the company confirmed that the deal is on track to close during the third quarter of 2026.

From a strategic standpoint, this divestiture allows Humana to streamline its portfolio and bolster its liquidity. The company has indicated that the proceeds from the sale will be allocated toward general corporate purposes. By offloading this non-core asset, Humana is likely looking to optimize its capital structure and focus resources on its primary health insurance and care delivery operations.

For investors and market analysts, the impact of this sale appears to be neutral in the near term. Humana has explicitly stated that it does not expect the transaction to have a material effect on its 2026 earnings. This move reflects a broader trend among major healthcare providers to refine their business models by exiting specialized service segments that may no longer align with their long-term growth objectives.